#ASCO18 A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, TKI naïve patients with advanced NSCLC: Pembrolizumab’s lack of efficacy in TKI naïve, PD-L1+, EGFR-mutant patients with advanced NSCLC, including those with PD-L1 expression ≥50%
#ASCO18 Merit Award and poster discussion for Dr Lisa Derosa : Gut microbiome composition to predict resistance in renal cell carcinoma (#RCC) patients on nivolumab. w/ #LaurenceZitvogel Abstract ▶️